Clinical Trial Update: ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Ultra-High-Risk Multiple Myeloma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is exploring autologous stem cell transplant followed by maintenance with BCMA CAR-T cells and GPRC5D/CD3 BiTEs for transplant-eligible…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• BCMA CAR-T
• GPRC5D/CD3 BiTE (GPRC5D/CD3 bispecific T-cell engager)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Multiple Myeloma, Newly Diagnosed | Phase 2 | Status: RECRUITING